Jamie Littlejohns

Burden of illness (BOI) and unmet need are key considerations for HTA decision makers, but how do manufacturers assess these when bringing a new medical treatment to market? In the first of our new how-to series Lumanity’s Matthew Woods explores the importance of understanding burden of illness and unmet need, as well as giving an overview of the key considerations when conducting reviews. Want to know more? Follow the link and download the guide. https://buff.ly/3WpGqzn #LumanityPerspectives #UnmetNeed #BOI #HEOR #HTA

23

1 Comment

Burden of illness (BOI) and unmet need are key considerations for HTA decision makers, but how do manufacturers assess these when bringing a new medical treatment to market? In the first of our new how-to series Lumanity’s Matthew Woods explores the importance of understanding burden of illness and unmet need, as well as giving an overview of the key considerations when conducting reviews. Want to know more? Follow the link and download the guide. https://buff.ly/3Ah7IRe #LumanityPerspectives #UnmetNeed #BOI #HEOR #HTA

3

💡 Check out the final segment of our 'Making Market Access Real' series focusing on Accelerating Innovation. Where our panel of experts Richard Stubbs, Chair of the National Health Innovation Network, Kate Woolland, Chief Operating Officer, Closed Loop Medicine, Jim McArdle, Strategy Lead, Patient Services, IQVIA and Paul Henderson, Director of Consulting, UK&I Healthcare & Government, IQVIA, dive into the crucial topic of cross-company adoption of innovation. Discover the importance of bringing together different organisations and focusing on pathways that align with your local healthcare system. Watch the video now!

32

Catch our COO Kate Woolland together with a panel of experts for the final segment of IQVIA UK and Ireland 's “Making Market Access Real” series, focusing on accelerating innovation.   This week’s segment transitions from discussing the challenges behind the implementation of innovative solutions in healthcare to the crucial topic of cross-company adoption of innovation. The panel highlights the importance of bringing together different organizations and focusing on pathways, alongside products, to successfully introduce innovations into the NHS, concluding with top tips for innovators.   At Closed Loop Medicine, our mission is to provide a pathway for all individuals to access high-quality personalized treatment, by enabling real-time, real-world drug dose optimization of both new and established medicines – offering precision care for all whilst supporting healthcare providers and addressing the current shortfall in scalable personalized healthcare solutions.   Listen to the full discussion below 👇   #Healthcare #Innovation #NHS #PrecisionCare

18

The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) have published new guidance on how the NHS can make the most of life science industry partnerships. The guidance includes key advice on how to make partnerships work and how to set them up with success in mind, including involving the community in the early planning stages. This new guidance is a very practical resource, bringing together existing frameworks and providing additional support for partnership working across primary, secondary, and system settings. It includes clear template forms to aid in understanding collaborative and joint working agreements. The guidance also incorporates case studies that illustrate the process of identifying, implementing, and monitoring prospective partnerships. By consolidating guidance for partnership working, this document seeks to equip system leaders with the tools and insights to support effective collaborations that will successfully drive positive health outcomes for patients.

9

Optimise your clinical trials with Initiate's Clinical Trial Positioning for HTA Success Review service 🔬 Are you ready to take your clinical trials to the next level? We offer a comprehensive Clinical Trial Positioning for HTA Success Review service to ensure your studies are designed for success from the start, with a focus on Health Technology Assessment (HTA) success. Get in touch if you would like to know more. [email protected] #clinicaltrials #hta #reimbursement #expertreview

7

On 24 April, Blue Matter convened a group of C-level executives from the UK #biotech industry to discuss a range of strategic topics. Here is a concise summary of the discussion & some key takeaways: https://lnkd.in/eQB9sEWd Authors: Damien Downes & Charlotte Culpin #pharmaceutical #biopharma #biotechnology

101

3 Comments

Are you wondering whether your digital health app needs regulatory approval in the UK? The NIHR Industry team can support you to navigate regulatory approvals in the UK. Get in touch today: https://lnkd.in/ed8frTKw #askNIHR #lifesciences #UKregulatoryapprovals

3

Are you wondering whether your digital health app needs regulatory approval in the UK? The NIHR Industry team can support you to navigate regulatory approvals in the UK. Get in touch today: https://lnkd.in/ed8frTKw #askNIHR #lifesciences #UKregulatoryapprovals

2

Are you wondering whether your digital health app needs regulatory approval in the UK? The NIHR Industry team can support you to navigate regulatory approvals in the UK. Get in touch today: https://lnkd.in/ed8frTKw #askNIHR #lifesciences #UKregulatoryapprovals

4

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 7𝘁𝗵 𝗡𝗛𝗦 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻 𝗠𝗮𝗻𝗰𝗵𝗲𝘀𝘁𝗲𝗿 Last week, Icon Group's Executive Manager Strategic Growth Aldo Rolfo, took to the stage at the Convenzis Group 7th NHS Oncology Conference in Manchester. This event brought together industry thought leaders to discuss the latest innovations and best practices in oncology care, and we are proud to have been part of it. Aldo’s presentation showcased Icon's journey and expertise in several cutting-edge areas including: – Remote overnight radiation treatment planning: revolutionising patient care with timely and efficient treatment plans, even when the world sleeps. – Enhanced patient experience: Leveraging a synergistic network of global expertise and local knowledge across all regions in which we operate. – Strategic partnerships: highlighting the immense value of collaborations in driving innovation and continuous improvement in oncology care. – And shared breaking news that Icon announced the acquisition of Pharmaxo in the UK. This creates greater vertical integration within the cancer care pathway, from specialist cancer drug compounding to treatment delivery, ensuring that every patient receives timely access to the best possible care close to home. Icon and Icon Cancer Centre - United Kingdom are committed to bringing the best cancer care possible, to as many people as possible, as close to home as possible, and we were grateful for the opportunity to share our story and contribute to this important conversation in Manchester. #cancercare #oncology #bestcarepossible #healthcareinnovation #strategicpartnerships #AtIconYouCan #convenzis #healthcareconference

79

4 Comments

🌟 MSD has now been PIF TICK re-certified This means their health information is: - Evidence-based - Up-to-date - Easy to use and understand Get PIF TICK certified: https://lnkd.in/eURpbSfF #HealthInformation #PIFTick

16

🔍 Disclosure recommendations for patient organisations 🔍 Our summary of the key points for patient organisations is below. The full guidance from The Association of the British Pharmaceutical Industry (ABPI) is here: https://lnkd.in/eeU-cPGn #abpicode #clarity #compliance #confidence #patientorganisations #disclosure #transparency #uk #pharma

3

The AI boom in health tech startups and scale-ups across Europe is set to have a real-world impact on the future of healthcare. This week, our SVP of Drug Discovery, Andrew Pierce, shared insights with Pharmaceutical Technology on this development. “We are our own clinical development company…we’re using the AI to inform our own decisions in clinical development, in addition to being able to partner with other pharma companies to help them make better AI-informed and enabled decisions in their studies.” 📰 Read the full article: https://lnkd.in/dzZ7XRz2

67

1 Comment

⏳ 5th September - Your chance to listen live to experts from Greenphire Timothy Dorsey, Steven Geffon, Dave Hine + Jaleeysa King https://lnkd.in/exixXBHA Recruiting and retaining patients for clinical trials can be challenging, dropout rates are around 30%. Sponsors are increasing payment and offering travel services to improve access, engagement, and diversity. How much should be budgeted for these critical solutions? Reserve your spot now to get the chance to learn more about: ☀ The burden associated with participating in a clinical trial ☀The best mix of clinical trial support ☀The tools to forecast and budget trial costs across phases, therapeutic areas and country ☀The ability to negotiate contracts with confidence

2

How do you achieve meaningful patient outcomes at scale? As part of our latest Life Sciences in the Spotlight episode, Jason C. Foster spoke to Niamh O'Donnell to explore the biotech landscape of the future and the importance of interventions that go beyond medicine and actually support patients and health systems to lower costs and improve outcomes beyond just a singular medical intervention. Take a quick listen below and for the full episode, visit: https://lnkd.in/d9KyPSCC #LifeSciences #PrecisionMedicine #PersonalisedMedicine #Pharma #PatientOutcomes

12

Get insights into the UK's strategic moves in life sciences, from regulatory reforms to international partnerships 🧫 https://buff.ly/4b6IX7J #medical #healthcareinnovation #medicalresearch #healthcare #biotech #scienceandtechnology #medtech #healthtech #technologyinnovation #medicaldevices #medicaldevice #diagnostics #diagnosis #diagnostictech #xray #osteoporosis #osteo #diagnostictechnology #technology #medicaltech #healthcaretechnology #medicalinnovation #FDA #science #medical #healthcareinnovation #medicalresearch #healthcare #immunotherapy #immunology #cancer #pharmaceuticals #precisionmedicine #pharma #pharmaceuticalindustry #oncology #scienceresearch #vaccine #medicalinnovation #drug #drugdevelopment #drugs #cancer

2